Part 2: Pain and Symptom Management

Constipation

Effective Date: February 22, 2017

Key Recommendations

- Prevent constipation by ordering a bowel protocol when regular opioid medication is prescribed.

Assessment

1. Understand the patient’s bowel habits, both current and when previously well (e.g., frequency of bowel movements (BMs), stool size, consistency, and ease of evacuation). Consider using the bowel performance scale available at: http://www.bccancer.bc.ca/family-oncology-network-site/Documents/BPSConstipationScale.pdf
2. The goal is to restore a patient’s normal BM frequency, consistency, and ease of passage.
3. For lower performance status patients (e.g., reduced food intake and activity), lower BM frequency is acceptable as long as there is no associated discomfort.

Management

1. There are many etiologies (e.g., reduced food/fluid/mobility and adverse effects of medications).
2. Exclude impaction when a patient presents already constipated. Abdominal x-ray can be useful when physical examination is inconclusive.
3. Minimize/avoid rectal interventions (enemas, suppositories, manual evacuation), except in crisis management. Note that rectal interventions are contraindicated when there is potential for serious infection (neutropenia) or bleeding (thrombocytopenia), or when there is rectal/anal disease.
4. When risk factors are ongoing, as they are in most cancer patients, suggest laxatives regularly versus prn. Adjust dose individually. Laxatives are most effective when taken via escalating dose according to response, termed “bowel protocol”.
5. Sennosides (e.g., Senokot®) are the first choice of laxative for prevention and treatment. Patients with irritable bowel syndrome may experience painful cramps with stimulant laxatives and often prefer osmotic laxatives such as lactulose or polyethylene glycol (PEG). There is weak evidence that lactulose and sennosides are equally effective; however lactulose can taste unpleasant and cause bloating.
6. If rectal measures are required, generally a stimulant suppository is tried first, then an enema as the next option.
7. The BC Palliative Care Drug Plan covers laxatives written on a prescription for eligible patients.
8. For patients with opioid-induced constipation, after a trial of first-line recommended stimulant laxatives and osmotic laxatives, methylnaltrexone (or nalaxegol) may be helpful. Cancer, GI malignancy, GI ulcer, Ogilvie's syndrome and concomitant use of certain medications (e.g., NSAIDs, steroids and bevacizumab) may increase the risk of GI perforation in patients receiving methylnaltrexone. [Health Canada MedEffect Notice: http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2010/14087a-eng.php]

1 BCGuidelines.ca: Palliative Care for the Patient with Incurable Cancer or Advanced Disease Part 2: Pain and Symptom Management – Constipation (2017)
Resources

 References

 Abbreviations
AEs    adverse effects
BM     bowel movement
GI     gastrointestinal
NSAIDs non-steroidal anti-inflammatory drugs
PEG    polyethylene glycol

 Appendices
Appendix A – Medications Used in Palliative Care for Constipation

For additional guidance on constipation, see also the BC Inter-professional Palliative Symptom Management Guidelines produced by the BC Centre for Palliative Care, available at: www.bc-cpc.ca/cpc/symptom-management-guidelines/
Appendix A: Medications Used in Palliative Care for Constipation

Tailor dose to each patient; those who are elderly, cachectic, debilitated or with renal or hepatic dysfunction may require reduced dosages; consult most current product monograph for this information:  [http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasдон/index-eng.php](http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasдон/index-eng.php)

<table>
<thead>
<tr>
<th>LAXATIVES&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Available Dosage Forms</th>
<th>Standard Adult Dose</th>
<th>Drug Plan Coverage&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Approx. cost per 30 days&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>bisacodyl</strong></td>
<td>Dulcolax®, G</td>
<td>Tabs: 5 mg</td>
<td>5 to 10 mg PO x 1 dose</td>
<td>Yes, LCA</td>
<td>No</td>
<td>$1 (G) $6 per 30 days</td>
</tr>
<tr>
<td>Supp: 10 mg</td>
<td>10 mg PR x 1 dose</td>
<td>$0.51 (G) per supp</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>sennosides</strong></td>
<td>Senokot®, G</td>
<td>Tabs: 8.6, 12 mg</td>
<td>2 tabs PO at bedtime to 3 tabs tid</td>
<td></td>
<td></td>
<td>$3–20 (G) $6–40 per 30 days</td>
</tr>
<tr>
<td>Oral syrup:</td>
<td>8.8 mg per 5 mL</td>
<td>10 mL PO at bedtime to 15 mL tid</td>
<td>Yes, LCA</td>
<td>No</td>
<td>$14–72 per 30 days</td>
<td></td>
</tr>
<tr>
<td><strong>glycerin supp&lt;sup&gt;d&lt;/sup&gt;</strong></td>
<td>G</td>
<td>Supp: 2.65 g</td>
<td>1 supp PR x 1 dose</td>
<td>Yes</td>
<td>No</td>
<td>$0.25 (G) per supp</td>
</tr>
<tr>
<td><strong>lactulose</strong></td>
<td>G</td>
<td>Oral solution: 667 mg per mL</td>
<td>15 mL PO daily to 30 mL PO bid</td>
<td>Yes, LCA</td>
<td>Special Authority, LCA</td>
<td>$7–28 (G) per 30 days</td>
</tr>
<tr>
<td><strong>polyethylene glycol 3350 (PEG)&lt;sup&gt;d&lt;/sup&gt;</strong></td>
<td>Lax-A-Day®, Pegalax®, RestoraLAX®, G</td>
<td>Powder: 17g sachets</td>
<td>17 grams in 250 mL fluid PO daily</td>
<td>No</td>
<td>No</td>
<td>$20–25 per 30 days</td>
</tr>
<tr>
<td><strong>sorbitol&lt;sup&gt;d&lt;/sup&gt;</strong></td>
<td>G</td>
<td>Oral solution: 70%</td>
<td>15 to 45 mL PO daily to qid</td>
<td>No</td>
<td>No</td>
<td>$10–136 (G) per 30 days</td>
</tr>
<tr>
<td><strong>glycerin-sodium citrate-sodium lauryl sulfoacetate-sorbit acid-sorbitol&lt;sup&gt;d&lt;/sup&gt;</strong></td>
<td>Microlax®</td>
<td>Micro-enema: 5 mL</td>
<td>5 mL PR x 1 to 2 doses</td>
<td>Yes</td>
<td>No</td>
<td>$1.80 per micro-enema</td>
</tr>
<tr>
<td><strong>phosphates enema&lt;sup&gt;h, e&lt;/sup&gt;</strong></td>
<td>Fleet enema®, G</td>
<td>Enema: 22 g per 100 mL</td>
<td>120 mL PR x 1 dose</td>
<td>Yes</td>
<td>No</td>
<td>$6 per enema</td>
</tr>
<tr>
<td><strong>mineral oil enema&lt;sup&gt;d&lt;/sup&gt;</strong></td>
<td>Fleet Enema Mineral Oil®</td>
<td>Enema: 130 mL</td>
<td>120 mL PR x 1 dose</td>
<td>Yes</td>
<td>No</td>
<td>$8 per enema</td>
</tr>
<tr>
<td><strong>methylnaltrexone&lt;sup&gt;o&lt;/sup&gt;</strong></td>
<td>Relistor&lt;sup&gt;®&lt;/sup&gt;</td>
<td>Inj: 12 mg per 0.6 mL</td>
<td>8 to 12 mg SC every 2 days</td>
<td>No</td>
<td>No</td>
<td>$616 per 30 days</td>
</tr>
<tr>
<td><strong>naloxegol</strong></td>
<td>Movantik®</td>
<td>Tabs: 12.5, 25 mg</td>
<td>25 mg PO once daily</td>
<td>No</td>
<td>No</td>
<td>$193 per 30 days</td>
</tr>
</tbody>
</table>

Abbreviations: G generics; LCA subject to Low Cost Alternative Program; PO by mouth; PR per rectum; SC subcutaneous; Supp suppositories (rectal); tabs tablet

<sup>a</sup> Refer to guideline and/or algorithm for recommended order of use.
<sup>b</sup> PharmaCare coverage as of October 2016 (subject to revision). Obtain current coverage, eligibility, and coverage information from the online BC PharmaCare Formulary Search page at [pharmacareformularysearch.gov.bc.ca](http://pharmacareformularysearch.gov.bc.ca).
<sup>c</sup> Cost as of October 2016 and does not include retail markups or pharmacy fees. Generic and brand name cost separated as indicated by (G).
<sup>d</sup> Cancer, gastrointestinal malignancy, gastrointestinal ulcer, Ogilvie's syndrome and concomitant use of certain medications (e.g., NSAIDs, steroids and bevacizumab) may increase the risk of GI perforation in patients receiving methylnaltrexone. [Health Canada MedEffect Notice: http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2010/14087a-eng.php](http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2010/14087a-eng.php)
<sup>h</sup> Contraindicated in patients with renal failure.

BCGuidelines.ca: Palliative Care for the Patient with Incurable Cancer or Advanced Disease